Mainstay Medical (EPA:MSTY) said that data from a trial of its ReActiv8 neurostim may be enough to win it CE Mark approval in the European Union and released its 6-month earnings today. The company’s multi-center, prospective ReActiv8-A clinical trial examined patients with chronic lower back pain treated with the company’s implantable ReActiv8 neurostimulation device. Of the […]
MassDevice Earnings Roundup
Accuray shares up on strong Q4, weak FY 2015 earnings
Accuray (NSDQ:ARAY) reported a strong 4th quarter as it saw losses grow faster than revenue for its fiscal year in an earnings report published yesterday. The company celebrated the largest volume of gross orders it’s seen since 2011, and a record grossing quarter for its CyberKnife system, according to an earnings conference call. “For the 4th quarter, […]
Sorin, Cyberonics jump after Italian court clears way for $3B merger
Shares of Sorin Group (BIT:SRN) and Cyberonics (NSDQ:CYBX) jumped today after the medical device companies said the way is clear for the consummation of their $2.7 billion merger. Sorin said a Milan court dismissed a claim brought by an Italian state attorney seeking to prevent Sorin from dodging a $3.76 billion environmental lawsuit filed against […]
Hill-Rom floats $425m debt offering for Welch-Allyn buy
Hill-Rom Holdings launched a $425 million round of debt financing to support its pending $2.05 billion purchase of Welch Allyn and its portfolio of point-of-care diagnostic devices, according to an SEC filing. The cash-and-stock deal is slated to leave privately owned Welch Allyn’s shareholders owning a 13% stake in Hill-Rom. The deal calls for Chicago-based Hill-Rom to pay $1.625 […]
SteadyMed still steady on Q2
SteadyMed Therapeutics (NASDAQ:STDY) yesterday released quarterly earnings that missed expectations and reported growing losses, but shares stayed steady. SteadyMed is a developer of hypertension and pain treatments given with a discrete, patented drug-delivery device called the PatchPump. The company is focusing on development and approval of Treyvant, a drug to treat pulmonary arterial hypertension. SteadyMed reported losses of […]
Staar Surgical updates on FDA warning, misses earnings on Q2
Staar Surgical (NSDQ:STAA) offered updates on the FDA warning it received in February as it released its quarterly earnings late last month. The company received a warning in February about its plant in Monrovia, Calif., where the company is headquartered. The FDA inspected the Monrovia facility from Nov. 14 last year through Feb. 4, finding 10 […]
Aethlon plans IDE, slims losses on Q1 report
Aethlon Medical (OTC:AEMD) yesterday said it plans to file for Investigative Device Exemption status for its HemoPurifier after the company’s contract with DARPA expires, and reports slimmed losses for the company and investors. In a quarterly earnings call, CEO Jim Joyce said this would be the company’s last year on contract with DARPA, with a caveat of a […]
Insulet shrinks losses but misses expectations on Q2
Insulet (NSDQ:PODD) released its 2nd quarter earnings yesterday after the closing bell on Wall Street, reporting shrinking losses but missing earnings and revenue analyst’s estimates by a fair margin. Insulet reported losses of $15.4 million, or 27¢ per share, on sales of $75.6 million for the 3 months ended June 30. That amounts to a […]
Glaukos sees losses widen in Q2
Glaukos (NYSE:GKOS) yesterday reported widening losses during its 2nd quarter, but shares held on for the glaucoma-treatment focused company. Laguna Hills, Calif.-based Glaukos reported losses of $32.5 million, or $10.96 per share, on sales of $17.8 million for the 3 months ended June 30. That amounts to a whopping 1000% plus increase in losses on sales […]
Titan Medical Q2 release shows development ramping up
Surgical robot developer Titan Medical (CVE:TMD) released its 2nd quarter earnings yesterday and reported on a handful of new agreements and operations as it continues towards production of its Sport surgical system. Titan Medical is developing a minimally invasive robotic surgical systems featuring its Single Port Orifice Robotic Technology with 3D imaging and interactive instruments. The company […]
Ocular Therapeutix slides as Q2 beats rev, misses earnings
Ocular Therapeutix (NSDQ:OCUL) announced its 2nd quarter earnings on Monday, beating expectations on revenue but missing on earnings. Ocular Therapeutics reported losses of $9.6 million, or 45¢ per share, on sales of $459,000 for the 3 months ended June 30. That amounts to a 62% increase in losses on sales growth of 373% compared with […]